DUBLIN–(BUSINESS WIRE)–The “Global Markets and Technologies for Optical Coherence Tomography (OCT)” report has been added to ResearchAndMarkets.com’s offering. Growth factors include technological advancement in OCT products, adoption of OCT systems in different application areas and strong investment in R&D activities by key market players, such as CarlZeiss Meditec Inc., Abbott and Topcon Medical Systems Inc., among others. Within the context of this report, the global markets and techn
Author: Business Wire
Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target=&…
The Global Market for Ophthalmic Lasers, 2019 to 2024 – Highest Revenues Expected for Refractive Error Corrections – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Lasers Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering. The ophthalmic lasers market is expected to register a CAGR of 4.9%, over the forecast period. Factors that are responsible for the growth of this market include high prevalence of ophthalmic disorders, increasing initiatives to control visual impairment, and increasing regulatory approvals for ophthalmic lasers. FDA is aware that there
Ophthalmology Drug and Device Market – Growth, Trends, and Forecast (2019 – 2024) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Drug and Device Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering. The ophthalmology drug and device market is expected to witness a CAGR of 5.3% during the forecast period. Certain factors that are driving the growth of the market include demographic shifts, the impact of the prevalence of eye disease, technological advancements in the field of ophthalmology, and a rising geriatric populat
BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target=&quo…
NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three months end…
Noveome Biotherapeutics, Inc. Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cells
PITTSBURGH–(BUSINESS WIRE)–Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announc…
Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the first…
Kala Pharmaceuticals Reports First Quarter 2019 Financial Results
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Deliv…
2019 Study on Myopia in the United States: Market Insights, Epidemiology and Forecast, 2017-2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Myopia – US Market Insights, Epidemiology and Market Forecast – 2028” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Myopia in the United States. The report provides the current treatment practices, emerging drugs, the market share of the individual therapies, the current and forecasted market size of Myopia fr
Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”) to Novartis and its T…
Glaukos Corporation Announces First Quarter 2019 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
Retinopathy of Prematurity: 2019 Pipeline Insights – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinopathy of Prematurity – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Retinopathy of Prematurity development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmenta
IVERIC bio Reports First Quarter 2019 Financial and Operating Results
NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced financial and operating results for the first quarter ended March 31, 2019 and provided a business update.
SAIC Awarded $58 Million U.S. Air Force Contract for Laser Research
RESTON, Va.–(BUSINESS WIRE)–The U.S. Air Force Research Laboratory selected Science Applications International Corp. (NYSE: SAIC) to research laser bioeffects, advance vision science, conduct modeling and simulation, and perform safety engineering, a…
Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the inc…
Mati Therapeutics Phase II Nepafenac Evolute® Clinical Trial Results Show Significant Post-Operative Pain Reduction in Cataract Surgery Patients
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that it has completed a Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute® sustained ocular punctal plug drug delive…
Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes. Omeros management …
前瞻性、多中心、樞紐臨床試驗顯示，Eyenuk用於糖尿病視網膜病變的人工智慧眼科篩檢系統有卓越表現
洛杉磯–(BUSINESS WIRE)–(美國商業資訊) — Eyenuk, Inc.是全球性人工智慧(AI)醫療科技及服務公司，也是AI Eye Screening™在真實世界應用的領導者，該公司今天宣佈具有里程碑意義的前瞻性、多中心、樞紐臨床試驗的結果，該試驗是驗證其用於糖尿病視網膜病變(DR)自主檢測的EyeArt® AI眼科篩檢系統，DR是致盲性疾病，據估計，到2030年全球患病人數將達到1.91億人1。研究結果在ARVO眼科影像會議上發表報告，報告人是伊利諾大學芝加哥分校眼科Mari…